Malignant Neoplasm — Trials

Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

90,710 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20,126
Recruiting: 10,896
Ph III recruiting: 1,279
Growth YoY: +12.3%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11,169)

clinicaltrialsPublishedShowing 651–700 of 8,374 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07779538	Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer	not yet recruiting	Phase 3	420	Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY	1	Aug 21, 2026	clinicaltrials
NCT04008030	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)(CheckMate 8HW)	active not recruiting	Phase 3	839	Bristol-Myers Squibb